MPG.eBooks - Description: CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee final recommendation: Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) indication : type 2 diabetes mellitus

The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, October 25, 2016
Series:	Common drug review
Subjects:	Insurance, Health, Reimbursement Metformin / Therapeutic Use Drug Combinations Canada Sodium-glucose Transporter 2 Inhibitors / Therapeutic Use Metformin / Economics Diabetes Mellitus, Type 2 / Drug Therapy Sodium-glucose Transporter 2 Inhibitors / Economics Drug Costs
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK532796
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin and metformin hydrochloride (empagliflozin/metformin) fixed-dose combination (FDC) be reimbursed for patients with type 2 diabetes mellitus
Physical Description:	1 PDF file (5 pages)